Role of L-citrulline in Prevention of Pregnancy Associated Hypertension

Gestational Hypertension Clinical Trial

Official title: Role of L-citrulline in Prevention of Pregnancy Associated Hypertension in Nulliparous Women

Status Suspended

Clinical Trial Summary

The target population for our study is healthy nulliparous pregnant women (first pregnancy) between the 12-16 week of pregnancy.

If a subject is eligible, written consent will be obtained by person to person contact. Eligible participants will be randomized to receive either daily L-citrulline supplementation or placebo.

Clinical Trial Description

Healthy nulliparous pregnant women (first pregnancy) between the 12-16 week of pregnancy will be eligible for this study. The purpose of this study will be to determine if daily supplementation of oral L-citrulline can reduce the incidence of pregnancy induced hypertension. This will be a double blind study, subjects will be randomized to receive either L-citrulline (3 gram sachet) or a placebo for a total of 8 weeks. Participants will be asked to provide urine and blood samples at time of enrollment, be asked to respond to a phone survey to assess for side effects, and again be asked to provide urine and blood samples at the end of 8 weeks. Participants will continue with routine prenatal care throughout the study. ;

Related Conditions & MeSH terms

• Eclampsia
• Gestational Hypertension
• Hypertension
• Hypertension, Pregnancy-Induced
• Pre-Eclampsia
• Preeclampsia and Eclampsia
• Pregnancy Induced Hypertension

• NCT number: NCT04979793
• Study type: Interventional
• Source: The University of Texas Medical Branch, Galveston
• Status: Suspended
• Phase: Phase 1
• Start date: July 28, 2021
• Completion date: July 30, 2024